Zacks Research Analysts Lower Earnings Estimates for PAHC

Phibro Animal Health Corporation (NASDAQ:PAHC) – Equities researchers at Zacks Research decreased their Q4 2026 earnings per share estimates for Phibro Animal Health in a report released on Tuesday, August 19th. Zacks Research analyst Team now anticipates that the company will earn $0.67 per share for the quarter, down from their prior forecast of $0.69. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2027 earnings at $0.63 EPS.

PAHC has been the topic of a number of other reports. Morgan Stanley set a $26.00 target price on shares of Phibro Animal Health and gave the company an “equal weight” rating in a research note on Wednesday, June 25th. BNP Paribas Exane raised Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price target on the stock in a research report on Monday, June 16th. Wall Street Zen upgraded Phibro Animal Health from a “hold” rating to a “buy” rating in a research note on Friday, May 9th. BNP Paribas raised Phibro Animal Health to a “hold” rating in a research report on Monday, June 16th. Finally, JPMorgan Chase & Co. raised Phibro Animal Health from a “neutral” rating to an “overweight” rating and raised their target price for the company from $25.00 to $35.00 in a report on Monday, July 7th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Phibro Animal Health presently has an average rating of “Reduce” and a consensus target price of $24.40.

Phibro Animal Health Trading Up 1.3%

NASDAQ:PAHC opened at $31.55 on Thursday. The company’s 50 day moving average is $28.14 and its 200-day moving average is $24.04. The company has a quick ratio of 1.23, a current ratio of 2.91 and a debt-to-equity ratio of 2.67. Phibro Animal Health has a 12 month low of $16.16 and a 12 month high of $32.45. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of 40.45, a P/E/G ratio of 0.52 and a beta of 0.80.

Institutional Trading of Phibro Animal Health

Institutional investors have recently modified their holdings of the company. Ranger Investment Management L.P. increased its position in shares of Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after purchasing an additional 179,975 shares during the period. State of Wyoming boosted its stake in Phibro Animal Health by 148.8% during the second quarter. State of Wyoming now owns 6,608 shares of the company’s stock worth $169,000 after buying an additional 3,952 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Phibro Animal Health by 768.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after buying an additional 4,079 shares during the period. State of Tennessee Department of Treasury increased its holdings in Phibro Animal Health by 18.6% in the 2nd quarter. State of Tennessee Department of Treasury now owns 26,743 shares of the company’s stock valued at $683,000 after buying an additional 4,200 shares during the period. Finally, Oxford Asset Management LLP acquired a new position in shares of Phibro Animal Health in the 2nd quarter valued at $485,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a yield of 1.5%. Phibro Animal Health’s dividend payout ratio is 61.54%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.